Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Xenon Pharmaceuticals (XENE) Tops Q2 EPS by 24c, Revenues Beat
August 6, 2020 5:03 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of $0.00, $0.24 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $13.38 million versus the consensus estimate of $6.9 million.
Dr. Simon Pimstone, Xenons Chief Executive Officer, said, Xenon continues to manage well as we respond to the global impacts of the COVID-19 pandemic. We are... More
